Thompson Siegel & Walmsley LLC Aurinia Pharmaceuticals Inc. Transaction History

Thompson Siegel & Walmsley LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 26, 2022	SELL	$10.05 - $22.48 $180,900 - $404,640	-18,000 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$17.78 - $33.08 $142,240 - $264,640	8,000 Added 80.0%	18,000 $412,000
Q3 2021 Nov 05, 2021	SELL	$10.93 - $23.55 $437,200 - $942,000	-40,000 Reduced 80.0%	10,000 $221,000
Q2 2021 Aug 09, 2021	BUY	$10.0 - $14.52 $190,000 - $275,880	19,000 Added 61.29%	50,000 $648,000
Q1 2021 May 07, 2021	BUY	$12.3 - $18.73 $196,800 - $299,680	16,000 Added 106.67%	31,000 $403,000
Q4 2020 Feb 08, 2021	BUY	$12.94 - $16.05 $194,100 - $240,750	15,000 New	15,000 $207,000

207

58.6M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.27B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Thompson Siegel & Walmsley LLC, based on Form 13F filings with the SEC.

Stay updated on Thompson Siegel & Walmsley LLC with notifications on news.